Unichem outlines manufacturing plan for generic Hyzaar

By Gareth Macdonald

- Last updated on GMT


Related tags Active pharmaceutical ingredients Hypertension

Unichem Laboratories Limited has confirmed it will make its generic version of Hyzaar for the US market at three plants in India.

The Mumbai-headquartered firm said it will make the active pharmaceutical ingredients (API) - losartan potassium and hydrochlorothiazide – at its facilities in Pithampur, Madhya Pradesh and Roha, Maharashtra.

Unichem also confirmed in a Bombay Stock Exchange (BSE) filing​ that it will make the finished formulation of the drug – which is a version of Merck & Co’s blood pressure pill - at its manufacturing facility in Ghaziabad, Uttar Pradesh.

The US Food and Drug Administration (FDA) approved Unichem’s version of the drug earlier this week.

Related news

Related product

Life Cycle Extension: A Molecule’s Full Potential

Life Cycle Extension: A Molecule’s Full Potential

Piramal Pharma Solutions | 16-Feb-2023 | Technical / White Paper

Winning approval for a new molecular entity is just a staging post on the journey of a drug. To maximize the benefits of a therapy, drugmakers need to...

Related suppliers

Follow us


View more